IS7051A - Lyfjasamsetningar - Google Patents

Lyfjasamsetningar

Info

Publication number
IS7051A
IS7051A IS7051A IS7051A IS7051A IS 7051 A IS7051 A IS 7051A IS 7051 A IS7051 A IS 7051A IS 7051 A IS7051 A IS 7051A IS 7051 A IS7051 A IS 7051A
Authority
IS
Iceland
Prior art keywords
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Application number
IS7051A
Other languages
English (en)
Inventor
Dixon John
Humphries Robert
Nicol Alexander
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IS7051A publication Critical patent/IS7051A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IS7051A 2001-05-31 2003-11-26 Lyfjasamsetningar IS7051A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0101932A SE0101932D0 (sv) 2001-05-31 2001-05-31 Pharmaceutical combinations
PCT/SE2002/001033 WO2002096428A1 (en) 2001-05-31 2002-05-29 Pharmaceutical combinations

Publications (1)

Publication Number Publication Date
IS7051A true IS7051A (is) 2003-11-26

Family

ID=20284321

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7051A IS7051A (is) 2001-05-31 2003-11-26 Lyfjasamsetningar

Country Status (24)

Country Link
US (2) US20040146498A1 (is)
EP (1) EP1397139A1 (is)
JP (1) JP2004532869A (is)
KR (1) KR20040003029A (is)
CN (1) CN100352442C (is)
AR (1) AR034343A1 (is)
AU (1) AU2002305952B2 (is)
BR (1) BR0210034A (is)
CA (1) CA2447648A1 (is)
CO (1) CO5550445A2 (is)
CZ (1) CZ20033246A3 (is)
EE (1) EE200300589A (is)
HU (1) HUP0400069A3 (is)
IL (1) IL158780A0 (is)
IS (1) IS7051A (is)
MX (1) MXPA03010761A (is)
NO (1) NO20035315D0 (is)
PL (1) PL366510A1 (is)
RU (1) RU2331422C2 (is)
SE (1) SE0101932D0 (is)
SK (1) SK14732003A3 (is)
TW (1) TWI232751B (is)
WO (1) WO2002096428A1 (is)
ZA (1) ZA200308780B (is)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6867199B2 (en) 2000-08-21 2005-03-15 Inspire Pharmaceuticals, Inc. Dinucleoside polyphosphate compositions and their therapeutic use
JP2004346067A (ja) * 2003-04-28 2004-12-09 Mitsubishi Pharma Corp 抗血栓薬の治療可能時間を延長するための薬剤
US7335648B2 (en) 2003-10-21 2008-02-26 Inspire Pharmaceuticals, Inc. Non-nucleotide composition and method for inhibiting platelet aggregation
US7749981B2 (en) 2003-10-21 2010-07-06 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound
JP2007509180A (ja) 2003-10-21 2007-04-12 インスパイアー ファーマシューティカルズ，インコーポレイティド 疼痛を治療するための、非ヌクレオチド組成物および方法
DE602004027409D1 (de) 2003-10-21 2010-07-08 Inspire Pharmaceuticals Inc Tetrahydrofuroä3,4-düdioxolverbindungen und zusammensetzungen und verfahren zur inhibierung der trombozytenaggregation
US7504497B2 (en) 2003-10-21 2009-03-17 Inspire Pharmaceuticals, Inc. Orally bioavailable compounds and methods for inhibiting platelet aggregation
JP2008517974A (ja) * 2004-10-25 2008-05-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗血栓薬と併用しての血栓塞栓性疾患の治療および予防のためのジピリダモールの使用
US7932376B2 (en) 2005-05-05 2011-04-26 Inspire Pharmaceuticals, Inc. Pyrimidine-based non-nucleotide composition and method for inhibiting platelet aggregation
US9532945B2 (en) * 2006-04-04 2017-01-03 Kg Acquisition Llc Oral dosage forms including an antiplatelet agent and an enterically coated acid inhibitor
JP2010508350A (ja) * 2006-10-31 2010-03-18 ヤンセン ファーマシューティカ エヌ．ベー． Ａｄｐｐ２ｙ１２レセプターアンタゴニストとしてのトリアゾロピリミジン誘導体
UA100864C2 (uk) * 2007-12-03 2013-02-11 Астразенека Аб Спосіб лікування або запобігання аневризмі черевної аорти
IN2012DN04412A (is) * 2009-11-09 2015-08-07 Alexion Pharmaceuticals Inc
US8883802B2 (en) * 2009-12-03 2014-11-11 Astrazeneca Ab Co-crystals of a triazolo [4,5-D] pyrimide platelet aggregation inhibitor
WO2011076401A1 (de) 2009-12-23 2011-06-30 Holger Schankin Acetylsalicylsäure-haltige, im wesentlichen wasserfreie pharmazeutische zusammensetzungen
ES2550033T3 (es) 2009-12-23 2015-11-04 Ratiopharm Gmbh Forma de dosificación farmacéutica sólida de ticagrelor
CN102653539B (zh) * 2011-03-01 2014-09-17 秦引林 一种抗血小板聚集化合物及其药物组合
JP2014516982A (ja) 2011-06-01 2014-07-17 アストラゼネカ アクチボラグ 新規なチカグレロル共結晶
CA2913326A1 (en) * 2013-05-29 2014-12-04 Ratiopharm Gmbh Solid pharmaceutical dosage form
CN104277039B (zh) * 2014-09-19 2016-06-01 广东东阳光药业有限公司 含有取代丁炔基的吡唑并哌啶酮类化合物及其组合物及用途
WO2016116942A1 (en) * 2015-01-20 2016-07-28 Anlon Chemical Research Organization Novel pharmaceutical compounds comprising ticagrelor with salts of aspirin
JP2018502894A (ja) * 2015-01-27 2018-02-01 アストラゼネカ アクチボラグ 心筋梗塞の病歴がある患者においてアテローム血栓性イベントを治療または予防する方法
CN106204544B (zh) * 2016-06-29 2019-04-05 南京中观软件技术有限公司 一种自动提取图像中标志点位置及轮廓的方法和系统

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9404196D0 (sv) * 1994-12-02 1994-12-02 Astra Ab New antithrombotic formulation
WO1997003084A1 (en) * 1995-07-11 1997-01-30 Astra Pharmaceuticals Ltd. New inhibitors of platelet aggregation
AR005245A1 (es) * 1995-12-21 1999-04-28 Astrazeneca Ab Prodrogas de inhibidores de trombina, una formulación farmaceutica que las comprende, el uso de dichas prodrogas para la manufactura de un medicamento y un procedimiento para su preparacion
FR2744918B1 (fr) * 1996-02-19 1998-05-07 Sanofi Sa Nouvelles associations de principes actifs contenant un derive de thieno(3,2-c)pyridine et un antithrombotique
TWI229674B (en) * 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
BR0010381A (pt) * 1999-03-11 2002-02-05 Du Pont Pharm Co Método de tratamento da trombose em um mamìfero, e uso de uma combinação de (i) um inibidor do fator xa, e (ii) um composto selecionado do grupo que consiste em aspirina, tpa, um antagonista gpiib/iiia, heparina de baixo peso molecular e heparina
AR023510A1 (es) * 1999-04-21 2002-09-04 Astrazeneca Ab Un equipo de partes, formulacion farmaceutica y uso de un inhibidor de trombina.
SE9904377D0 (sv) * 1999-12-01 1999-12-01 Astra Pharma Prod Pharmaceutical combinations

Also Published As

Publication number Publication date
CZ20033246A3 (cs) 2004-02-18
RU2331422C2 (ru) 2008-08-20
NO20035315D0 (no) 2003-11-28
SK14732003A3 (sk) 2004-05-04
AU2002305952B2 (en) 2007-08-09
SE0101932D0 (sv) 2001-05-31
WO2002096428A1 (en) 2002-12-05
BR0210034A (pt) 2004-08-10
AR034343A1 (es) 2004-02-18
JP2004532869A (ja) 2004-10-28
EP1397139A1 (en) 2004-03-17
US20060189584A1 (en) 2006-08-24
RU2003133216A (ru) 2005-04-20
CA2447648A1 (en) 2002-12-05
HUP0400069A2 (hu) 2004-04-28
ZA200308780B (en) 2005-02-11
US20040146498A1 (en) 2004-07-29
PL366510A1 (en) 2005-02-07
CO5550445A2 (es) 2005-08-31
MXPA03010761A (es) 2004-03-02
IL158780A0 (en) 2004-05-12
KR20040003029A (ko) 2004-01-07
CN100352442C (zh) 2007-12-05
HUP0400069A3 (en) 2006-02-28
CN1512885A (zh) 2004-07-14
TWI232751B (en) 2005-05-21
EE200300589A (et) 2004-02-16

Similar Documents

Publication Publication Date Title
FI20011478L (fi) Farmaseuttinen koostumus
AR028204A1 (es) Composiciones farmaceuticas electrohiladas
FI20105657L (fi) Farmaseuttisia koostumuksia
NO20033556L (no) Farmasöytiske formuleringer
ITMI20010748A0 (it) Composizioni farmaceutiche
PL367180A1 (pl) Trwała kompozycja farmaceutyczna
NO20033384D0 (no) Farmasöytisk formulering
EE200300416A (et) Ravimvorm
FI20010780A0 (fi) Parannetut koostumukset
DK1524266T3 (da) Farmaceutisk sammensætning
EE200300589A (et) Ravimkoostised
BR0210619A (pt) composição
NO20035627D0 (no) Farmasöytisk formulering
NO20026123L (no) Farmasöytiske sammensetninger
FI20022128A0 (fi) Farmaseuttinen koostumus
NO20031095D0 (no) Farmasöytiske sammensetninger
DK1429753T3 (da) Farmaceutisk sammensætning omfattende gamma-butyrobetain
EE200300465A (et) Püridoindolooni derivaatidel põhinevad farmatseutilised kompositsioonid
DE60200104D1 (de) Desodorierende Zusammensetzung
NO20044164L (no) Farmasoytiske sammensetninger
EE200300378A (et) Farmatseutiline kompositsioon
EE200200689A (et) Ravimkoostised
EP1413314A4 (en) MEDICAL COMPOSITIONS
FI5468U1 (fi) Farmaseuttinen koostumus
NO20041236L (no) Farmasoytisk formulering